Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/ADMA Biologics refutes misleading short-seller report, affirming compliance and reviewing claims.
ADMA
$8.86
+$0.18 +2.07%

ADMA Biologics refutes misleading short-seller report, affirming compliance and reviewing claims.

Market News
25 Mar 2026
GlobeNewsWire
View Source
Neutral
pluang ai news

ADMA Biologics has publicly addressed and rejected a recent short-seller report by Culper Research, which the company says contains false and misleading statements based on unreliable sources. ADMA emphasized its commitment to accurate financial reporting and regulatory compliance under U.S. SEC rules and GAAP standards. The company is currently reviewing the assertions made in the report. This response aims to reassure investors amid the short position held by Culper Research in ADMA's stock.

More News (ADMA)

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege the companies made f...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App